Yun-Hong Zhan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Renal cell carcinoma (RCC) is the most lethal of all urological cancers and tumor angiogenesis is closely related with its growth, invasion, and metastasis. Recent studies have suggested that epidermal growth factor-like domain multiple 7 (EGFL7) is overexpressed by many tumors, such as colorectal cancer and hepatocellular carcinoma; it is also correlated(More)
Renal-cell carcinoma (RCC) is the most common type of kidney cancer. About 30% of RCC patients are diagnosed as the late phase diseases, missing the opportunity of taking curative surgical excision. RCC is resistant to almost all the chemotherapeutics and radiation therapy. Immunotherapy is the major treatment for the late phase disease, but the response(More)
BACKGROUND Renal-cell carcinoma (RCC) is resistant to almost all chemotherapeutics and radiation therapy. β-Elemene, a promising anticancer drug extracted from a traditional Chinese medicine, has been shown to be effective against various tumors. In the present study, anti-tumor effects on RCC cells and the involved mechanisms were investigated. METHODS(More)
  • 1